HRP20030870B1 - Aripiprazole oral solution - Google Patents

Aripiprazole oral solution

Info

Publication number
HRP20030870B1
HRP20030870B1 HR20030870A HRP20030870A HRP20030870B1 HR P20030870 B1 HRP20030870 B1 HR P20030870B1 HR 20030870 A HR20030870 A HR 20030870A HR P20030870 A HRP20030870 A HR P20030870A HR P20030870 B1 HRP20030870 B1 HR P20030870B1
Authority
HR
Croatia
Prior art keywords
acid
oral solution
aripiprazole
solution
aripiprazole oral
Prior art date
Application number
HR20030870A
Other languages
English (en)
Croatian (hr)
Inventor
Parab Prakash
Chou Joyce
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030870(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20030870A2 publication Critical patent/HRP20030870A2/hr
Publication of HRP20030870B1 publication Critical patent/HRP20030870B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20030870A 2001-04-25 2003-10-24 Aripiprazole oral solution HRP20030870B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25
PCT/US2002/013048 WO2002085366A1 (en) 2001-04-25 2002-04-24 Aripiprazole oral solution

Publications (2)

Publication Number Publication Date
HRP20030870A2 HRP20030870A2 (en) 2004-06-30
HRP20030870B1 true HRP20030870B1 (en) 2011-10-31

Family

ID=23099862

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030870A HRP20030870B1 (en) 2001-04-25 2003-10-24 Aripiprazole oral solution

Country Status (37)

Country Link
US (1) US6977257B2 (xx)
EP (2) EP2436384B2 (xx)
JP (1) JP4401077B2 (xx)
KR (1) KR100909329B1 (xx)
CN (1) CN1512884B (xx)
AR (1) AR033168A1 (xx)
AT (1) ATE537831T1 (xx)
AU (1) AU2002254722B2 (xx)
BG (1) BG66177B1 (xx)
BR (1) BR0208986A (xx)
CA (1) CA2445276C (xx)
CY (1) CY1112606T1 (xx)
CZ (1) CZ306181B6 (xx)
DK (1) DK1381367T3 (xx)
EE (1) EE05581B1 (xx)
ES (1) ES2377855T3 (xx)
GE (1) GEP20053602B (xx)
HK (2) HK1058316A1 (xx)
HR (1) HRP20030870B1 (xx)
HU (1) HU230456B1 (xx)
IL (2) IL158202A0 (xx)
IS (1) IS2863B (xx)
MX (1) MXPA03009728A (xx)
MY (1) MY129350A (xx)
NO (1) NO324606B1 (xx)
NZ (1) NZ528550A (xx)
PE (1) PE20021086A1 (xx)
PL (1) PL206882B1 (xx)
PT (1) PT1381367E (xx)
RS (1) RS52082B (xx)
RU (1) RU2295960C2 (xx)
SK (1) SK287948B6 (xx)
TW (1) TWI337865B (xx)
UA (1) UA76144C2 (xx)
UY (1) UY27273A1 (xx)
WO (1) WO2002085366A1 (xx)
ZA (1) ZA200307797B (xx)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
DE60327225D1 (de) * 2002-08-20 2009-05-28 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
JP4836797B2 (ja) * 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
CA2552988A1 (en) * 2004-01-21 2005-08-04 Janssen Pharmaceutica Nv Mitratapide oral solution
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8865722B2 (en) * 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
CN101351193A (zh) * 2006-01-05 2009-01-21 特瓦制药工业有限公司 阿立哌唑的干法制剂
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
ATE523602T1 (de) 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
DK2170279T3 (en) * 2007-07-31 2018-03-12 Otsuka Pharma Co Ltd PROCEDURES FOR PREPARING AN ARIPIPRAZOL SUSPENSION AND A FREEZER DRIED FORMULATION
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
WO2010146872A1 (ja) * 2009-06-19 2010-12-23 株式会社メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
EP2609923B1 (en) 2010-03-31 2017-05-24 Gilead Pharmasset LLC Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
HUE065359T2 (hu) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
US9241876B2 (en) 2011-06-27 2016-01-26 Shanghai Zhongxi Pharmaceutical Corporation Aripiprazole medicament formulation and preparation method therefor
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US20150174247A1 (en) * 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9452134B2 (en) * 2012-09-26 2016-09-27 Bristol-Myers Squibb Company Apixaban solution formulations
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US20140107130A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals, LLC Oral Solution Formulations of Aripiprazole
PL2908859T3 (pl) * 2012-10-16 2017-10-31 Arven Ilac Sanayi Ve Ticaret As Formulacje arypiprazolu
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) * 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (xx) * 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
WO1998043673A1 (en) * 1997-03-31 1998-10-08 Johnson & Johnson Consumer Companies, Inc. Solvent system for enhanced penetration of pharmaceutical compounds
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
JP2002524397A (ja) * 1998-09-03 2002-08-06 アルサイド コーポレーション 耐凍結性の局所用殺菌剤及びそれに関連する方法
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives

Also Published As

Publication number Publication date
UA76144C2 (uk) 2006-07-17
HU230456B1 (hu) 2016-07-28
KR100909329B1 (ko) 2009-07-24
DK1381367T3 (da) 2012-04-10
AR033168A1 (es) 2003-12-03
US20020193438A1 (en) 2002-12-19
RS52082B (sr) 2012-06-30
HRP20030870A2 (en) 2004-06-30
CA2445276C (en) 2009-10-13
EP2436384A2 (en) 2012-04-04
EE200300523A (et) 2004-02-16
UY27273A1 (es) 2002-11-29
HUP0303946A3 (en) 2005-06-28
EP2436384A3 (en) 2012-09-19
BR0208986A (pt) 2004-04-20
ATE537831T1 (de) 2012-01-15
BG108216A (bg) 2004-12-30
BG66177B1 (bg) 2011-11-30
HK1058316A1 (en) 2004-05-14
PE20021086A1 (es) 2002-12-14
CY1112606T1 (el) 2016-02-10
RU2003132426A (ru) 2005-04-20
CZ306181B6 (cs) 2016-09-14
GEP20053602B (en) 2005-08-10
IS2863B (is) 2013-12-15
NO20034705D0 (no) 2003-10-21
MY129350A (en) 2007-03-30
CN1512884A (zh) 2004-07-14
ES2377855T3 (es) 2012-04-02
NO20034705L (no) 2003-11-28
IS6994A (is) 2003-10-14
TWI337865B (en) 2011-03-01
WO2002085366A1 (en) 2002-10-31
JP2004532225A (ja) 2004-10-21
CZ20032821A3 (cs) 2004-09-15
CN1512884B (zh) 2010-05-26
IL158202A (en) 2008-04-13
PL364666A1 (en) 2004-12-13
HK1168792A1 (en) 2013-01-11
HUP0303946A2 (hu) 2004-04-28
ZA200307797B (en) 2004-10-06
EP1381367B1 (en) 2011-12-21
SK287948B6 (sk) 2012-06-04
CA2445276A1 (en) 2002-10-31
EP1381367A1 (en) 2004-01-21
PT1381367E (pt) 2012-03-01
YU84703A (sh) 2006-08-17
JP4401077B2 (ja) 2010-01-20
EP2436384B2 (en) 2018-05-23
AU2002254722B2 (en) 2006-11-09
IL158202A0 (en) 2004-05-12
SK12642003A3 (sk) 2004-07-07
EP1381367A4 (en) 2009-07-01
KR20030096332A (ko) 2003-12-24
EP2436384B1 (en) 2015-06-10
RU2295960C2 (ru) 2007-03-27
NZ528550A (en) 2005-03-24
MXPA03009728A (es) 2004-01-29
NO324606B1 (no) 2007-11-26
PL206882B1 (pl) 2010-10-29
EE05581B1 (et) 2012-10-15
US6977257B2 (en) 2005-12-20

Similar Documents

Publication Publication Date Title
HRP20030870B1 (en) Aripiprazole oral solution
RS50360B (sr) Farmaceutske formulacije derivata platine
HRP20010332B1 (en) Pharmaceutical moxifloxacin preparation
MX9600857A (es) Forma de dosificacion i en tabletas, con unidades multiples.
WO2005045689A3 (en) Methods and systems for network coordination
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
DE69627147D1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
RS51737B (sr) Korišćenje inhibitora il-18
ATE304013T1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ME00578A (en) Use of gastrointestinal lipase inhibitors
HRP20030050B1 (en) Sustained-release preparations of quinolone antibiotics and method for preparation thereof
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
NO20026212L (no) Forbindelse for medikamentavleveringssystem og fremgangsmåte for fremstilling av forbindelsen
DE60138629D1 (de) Laspartomycin-derivate, sowie ihre herstellung und verwendung
DE69711633D1 (de) Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung
TR199903065T2 (xx) Oral uygulamaya y�nelik rapamisin form�lasyonlar�.
NO994679L (no) Quinolin-2-karboksylsyrederivat og anvendelse derav som eksitatorisk aminosyreantagonist
HRP20000703B1 (en) Stabile compositions levosimendan and alginic acid
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
DE60029979D1 (de) LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT
NO20041878D0 (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: BRISTOL-MYERS SQUIBB COMPANY, US

PPPP Transfer of rights

Owner name: OTSUKA PHARMACEUTICAL CO., LTD., JP

ODRP Renewal fee for the maintenance of a patent

Payment date: 20180410

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20190424